

Francesco Gaudio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6136363/publications.pdf>

Version: 2024-02-01

38
papers

634
citations

623188

14
h-index

610482

24
g-index

39
all docs

39
docs citations

39
times ranked

998
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas. <i>Journal of Clinical Pathology</i> , 2022, 75, 493-497.	1.0	10
2	In male Hodgkin lymphoma patients, impaired fertility may be improved by nonâ€gonadotoxic therapy. <i>British Journal of Haematology</i> , 2022, 196, 110-115.	1.2	2
3	Serological response following BNT162b2 antiâ€SARSâ€CoVâ€2 mRNA vaccination in haematopoietic stem cell transplantation patients. <i>British Journal of Haematology</i> , 2022, 196, 928-931.	1.2	20
4	The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells. <i>Diagnostics</i> , 2022, 12, 573.	1.3	3
5	Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1257.	1.0	5
6	INDOLENT LYMPHOPROLIFERATIVE T-CELL DISORDERS ASSOCIATED WITH GASTROINTESTINAL DISEASE: DIAGNOSTIC CHALLENGES AND OUTCOMES. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	2
7	Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2021, 21, 573-578.	1.9	4
8	STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 567-574.	0.6	19
9	Inflammatory Cells in Diffuse Large B Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2418.	1.0	29
10	Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e506-e512.	0.2	7
11	Relapsing/refractory HL after autotransplantation: which treatment?. <i>Acta Biomedica</i> , 2020, 91, 30-40.	0.2	0
12	Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkinâ€™s lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1947-1952.	0.8	11
13	Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkinâ€™s lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1449-1455.	0.8	8
14	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e321-e323.	0.2	0
15	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€™Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	1.9	10
16	STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma. <i>Translational Oncology</i> , 2019, 12, 545-549.	1.7	14
17	Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 35-40.	0.2	10
18	Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e261-e266.	0.2	6

#	ARTICLE	IF	CITATIONS
19	Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. <i>Annals of Hematology</i> , 2018, 97, 663-668.	0.8	8
20	Bone Involvement in Hodgkin's Lymphoma: Clinical Features and Outcome. <i>Acta Haematologica</i> , 2018, 140, 178-182.	0.7	21
21	Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2018, 97, 1817-1824.	0.8	9
22	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
23	Risk of lymphoma subtypes by occupational exposure in Southern Italy. <i>Journal of Occupational Medicine and Toxicology</i> , 2017, 12, 31.	0.9	13
24	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	0.8	21
25	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
26	T cells, mast cells and microvascular density in diffuse large B cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2016, 16, 301-306.	1.9	17
27	Computed tomography-guided needle biopsy performed with modified coaxial technique in patients with suspected lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1949-1951.	0.6	0
28	Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1596-1601.	0.6	5
29	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. <i>Leukemia Research</i> , 2014, 38, 1446-1450.	0.4	13
30	Microvascular density, CD68 and tryptase expression in human Diffuse Large B-Cell Lymphoma. <i>Leukemia Research</i> , 2014, 38, 1374-1377.	0.4	44
31	CT-guided needle biopsy performed with modified coaxial technique in patients with refractory or recurrent lymphomas. <i>Annals of Hematology</i> , 2014, 93, 1559-1564.	0.8	3
32	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	0.6	40
33	Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation by Donor Graft CD3+/Tregs Ratio: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 495-499.	2.0	18
34	CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 887-893.	2.0	27
35	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	0.6	123
36	Recovery of CMV-Specific CD8+ T Cells and Tregs after Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 550-557.	2.0	31

#	ARTICLE	IF	CITATIONS
37	Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas. <i>Advances in Hematology</i> , 2011, 2011, 1-6.	0.6	17
38	High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. <i>Acta Haematologica</i> , 2011, 126, 44-51.	0.7	48